Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year

Article

Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.

psoriasis

A cohort analysis of plaque psoriasis patients treatment in real-world US dermatology referral practices showed that a majority of those treated with ixekizumab achieved clear skin within 3 months.

In new data presented at the American Academy of Dermatology (AAD) 2019 Annual Meeting in Washington, DC, this week, investigators from the US and Canada showed real-world disease severity and quality of life improvements in patients treated with monoclonal antibody ixekizumab. Marketed as Taltz, the Eli Lilly & Company biologic was previously approved for the treatment of plaque psoriasis by the US Food and Drug Administration (FDA) in March 2016.

Ixetizumab binds and blocks interleukin 17 (IL-17) in patients, preventing the pro-inflammatory cytokine from stimulating proliferation and keratinocyte activiation in the skin of patients with plaque psoriasis.

Investigators—led by Craig Leonardi, MD, of Central Dermatology in St. Louis, MO—conducted a cohort analysis of patients treated at a St. Louis-based dermatology practice. The team sought to assess plaque psoriasis severity and quality of life (QoL) in three-month intervals of patients treated with ixekizumab over their first year.

The patient population were 106 adults (median age 47.9 years), 93% Caucasian and 67% male. Another 95% were privately insured. About three-fourths (74%; n= 78) of patients had received previous biologic therapy for their psoriasis—most commonly a tumor necrosis fact (TNF) alpha inhibitor (n= 47), secukinumab (n= 27), and/or ustekinumab (n= 12). Approximately half (52%) had previously received systemic therapy including methotrexate, and another half (51%) received topical treatment.

Investigators assessed the patients’ scores for body surface area (BSA), static Physician Global Assessments (sPGA), and Dermatology QoL Index (DLQI) at 1 month post-index, and at three-month intervals both pre- and post-index.

By 1 month, more than half of the observed patients (59%) had achieved clear or nearly clear skin (sPGA scores of 0 or 1), and most (70%) had achieved BSA ≤1%. At 3 months, 74% of patients had achieved clear or nearly clear skin, and another 84% had achieved BSA ≤ 1%.

In assessing for treatment duration at 12 months, investigators found 63% of patients still reported scores of 0 or 1 for sPGA, and 82% achieved BSA ≤ 1%. Median decrease from each time point was approximately 3% for BSA, and about 2 points for both sPGA and DLQI scores. These scores were assessed in the 74% (n= 78) of patients in the cohort to continue ixekizumab treatment through 1 year.

At 12 months, 66.7% (n= 48) of patients reported a DLQI score of 0-1, indicating the psoriasis had “no effect” on their life. Another 15.3% (n= 11) reported it as just having a “small effect” on their life, as indicated by a score of 2-5.

According to investigators, the BSA ≤ 1% score is a target set by the National Psoriasis Foundation (NPF) for treatment. More than 80% of ixekizumab-treated patients achieved this target at three- and six-month intervals.

Investigators concluded the biologic is associated with quick improvements in disease severity and QoL, with one-year sustained effects. That said, they also called for larger multi-site studies to corroborate their findings.

The study, “Disease Severity and Quality of Life among Ixekizumab-Treated Psoriasis Patients in the Real-World Setting: Results from a Single US Dermatology Referral Practice,” were presented at AAD 2019.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
© 2024 MJH Life Sciences

All rights reserved.